pemetrexed+cisplatin

DRUG2 trials

Sponsors

AstraZeneca, Yonsei University

Conditions

Non-small Cell Lung Cancer NSCLCSarcoma,Soft Tissue

Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruitingNCT03775486

AstraZenecaNon-small Cell Lung Cancer NSCLC

Start: 2018-12-21End: 2026-09-27Updated: 2026-02-10

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

RecruitingNCT04605770

Yonsei UniversitySarcoma,Soft Tissue

Start: 2020-12-22End: 2027-11-01Target: 164Updated: 2024-12-18

Related Papers

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

2023-06-298 citations

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.

2022-08-1136 citations

Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.

2021-09-023 citations

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-204 citations